Loading...
Loading...
African Journal of Biology and Medical Research
Vol. 7Issue 22024pp. 144–161Published 7 June 2024
DOI 10.52589/AJBMR-CJXIGIKVShare Link
Cite this
Citation unavailable for this article.
Abstract:
The clog in the wheel of progress in management of infectious diseases has necessitated a continuous search for suitable bioactive agents for desired relief. Thus this work was to specifically screen previously isolated, newly discovered fungi species for bioactive agents. The fungi species – Purpureocillium sp was used to produce a crude antibiotic substance, extracted with acetone and tested on clinical isolates – Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans. The result of zones of inhibition was 20mm, 15mm, 16mm, 0mm and 20mm in order of listing of the organisms. The result of GC-MS test pin-points these compounds – t-9-octadecenoic acid, oleic acid, hexadecanoic acid methyl ester, z-9-octadecenamide, hexadecanoic acid and methylene chloride as been responsible for observed inhibition. The fungus was also used to produce a crude amylase and tested it on clinical organisms as above with no antibiotic activity. The enzyme activity of the crude enzyme was 70U/L. The antibiotic product holds a promise for a desired drug for mixed microbial infection just like the enzyme which can be coupled to a nano silver particle for drug delivery.
Disclaimer/Publisher’s Note
The statements, opinions and data contained in this publication are solely those of the author(s) and contributor(s) and not of AB Journals or its editors. AB Journals remains neutral and accepts no responsibility for any injury or damage resulting from ideas, methods, instructions or products referred to in the content.
Copyrights